Health
Factlen Explainer
Landmark Phase 3 Trial Finds Single-Dose Psilocybin Provides Six-Month Relief for Severe Depression
6 sources · 15d ago
Factlen Explainer
Landmark Phase 3 Trial Finds Single-Dose Psilocybin Provides Six-Month Relief for Severe Depression
6 sources · 15d ago
Factlen Explainer
Landmark Study: Global Food Fortification Prevents 7 Billion Nutrient Gaps Annually, Could Triple Impact
6 sources · 15d ago
More in Health
Factlen ExplainerFood Fortification
Landmark Study: Global Food Fortification Prevents 7 Billion Nutrient Gaps Annually, Could Triple Impact
Public Health Experts 50%Food Industry & Millers 30%Dietary Diversity Advocates 20%
6 sources · 15d ago
Precision OncologyExplainer
Landmark Trial: Eli Lilly Drug Slashes Early-Stage Lung Cancer Recurrence Risk by 83%
Clinical Oncologists 45%Patient Advocates 35%Pharmaceutical Industry 20%
3 sources · 16d ago
Factlen ResearchMetabolic Disease
Landmark Phase 3 Trial: New Oral GLP-1 Pill Orforglipron Outperforms Semaglutide for Weight Loss and Diabetes Control
Metabolic Disease Specialists 40%Pharmaceutical Analysts 35%Clinical Cautious Voices 25%
4 sources · 16d ago
Factlen ExplainerPain Management
FDA Approves First-in-Class Oral Non-Opioid Drug for Acute Pain, Offering Alternative to Addictive Narcotics
Pain Medicine Specialists 35%Addiction Recovery Advocates 35%Biomedical Researchers 30%
8 sources · 16d ago
Factlen ExplainerPain Management
FDA Approves First-in-Class Oral Non-Opioid Drug for Acute Pain, Offering Alternative to Addictive Narcotics
Pain Medicine Specialists 35%Addiction Recovery Advocates 35%Biomedical Researchers 30%
8 sources · 16d ago
Factlen ExplainerIgA Nephropathy
The Evidence Pack: How a First-in-Class Dual Inhibitor is Rewriting the Treatment of IgA Nephropathy
Nephrology Researchers 40%Patient Advocacy Groups 35%Regulatory & Safety Watchdogs 25%
6 sources · 17d ago
Factlen ExplainerIgA Nephropathy
The Evidence Pack: How a First-in-Class Dual Inhibitor is Rewriting the Treatment of IgA Nephropathy
Nephrology Researchers 40%Patient Advocacy Groups 35%Regulatory & Safety Watchdogs 25%
6 sources · 17d ago
Factlen ExplainerACA Subsidies
What the Expiration of Enhanced ACA Subsidies Means for Health Coverage in 2026
Health Policy Researchers 40%Federal Administrators 35%Healthcare Providers 25%
3 sources · 17d ago
Factlen ExplainerMetabolic Psychiatry
Landmark Research Suggests Mental Illness Starts in Brain Cells, Shifting Focus From Neurotransmitters to Cellular Metabolism
Metabolic Psychiatry Pioneers 45%Traditional Neurobiologists 35%Clinical Innovators 20%
4 sources · 17d ago
Factlen ExplainerMetabolic Psychiatry
Landmark Research Suggests Mental Illness Starts in Brain Cells, Shifting Focus From Neurotransmitters to Cellular Metabolism
Metabolic Psychiatry Pioneers 45%Traditional Neurobiologists 35%Clinical Innovators 20%
4 sources · 17d ago
Dental RegenerationExplainer
First-in-Class Antibody Targeting USAG-1 Enters Human Trials to Regrow Teeth Naturally
Regenerative Medicine Researchers 40%Mainstream Science Observers 35%Clinical Dentists & Prosthodontists 25%
3 sources · 17d ago
Dental RegenerationExplainer
First-in-Class Antibody Targeting USAG-1 Enters Human Trials to Regrow Teeth Naturally
Regenerative Medicine Researchers 40%Mainstream Science Observers 35%Clinical Dentists & Prosthodontists 25%
3 sources · 17d ago
Factlen ResearchADHD Innovation
First-in-Class NDSRI Centanafadine Poised to Reshape ADHD Treatment for All Ages
Clinical Psychiatrists 40%Neuropharmacology Researchers 30%Patient Advocates 30%
6 sources · 17d ago
Factlen ResearchADHD Innovation
First-in-Class NDSRI Centanafadine Poised to Reshape ADHD Treatment for All Ages
Clinical Psychiatrists 40%Neuropharmacology Researchers 30%Patient Advocates 30%
6 sources · 17d ago
Factlen ExplainerWomen's Health
How a New Androgen 'Fingerprint' is Making Non-Surgical Endometriosis Diagnosis a Reality
Clinical Researchers 40%Patient Advocates 35%Public Health Officials 25%
5 sources · 17d ago
Factlen ExplainerPsychedelic Therapy
The Evidence Pack: How the White House Mandate is Accelerating Psychedelic Medicine
Clinical Researchers & Drug Sponsors 40%Veteran & Patient Advocates 35%Regulatory Skeptics 25%
6 sources · 17d ago
Factlen ExplainerPsychedelic Therapy
The Evidence Pack: How the White House Mandate is Accelerating Psychedelic Medicine
Clinical Researchers & Drug Sponsors 40%Veteran & Patient Advocates 35%Regulatory Skeptics 25%
6 sources · 17d ago
Factlen ExplainerPreventive Cardiology
The Evidence Pack: How Repatha is Rewriting the Rules of Primary Heart Disease Prevention
Preventive Cardiology Consensus 45%Health Economics & Payers 35%Patient Advocacy 20%
5 sources · 17d ago
Factlen ResearchSenolytics
The Evidence Pack: How Reprogrammed CAR-T Cells Are Eliminating 'Zombie Cells' to Reverse Aging in Mice
Cellular Biologists 35%Translational Gerontologists 35%Health Economists 30%
5 sources · 17d ago
Sleep ApneaExplainer
FDA Approves First-Ever Drug Treatment for Obstructive Sleep Apnea
Sleep Medicine Specialists 40%Patient Advocacy Groups 35%Medical Device Industry 25%
2 sources · 18d ago
Sleep ApneaExplainer
FDA Approves First-Ever Drug Treatment for Obstructive Sleep Apnea
Sleep Medicine Specialists 40%Patient Advocacy Groups 35%Medical Device Industry 25%
2 sources · 18d ago